menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Qilu Pharma Unveils Results for QLS32015 Bispecific Antibody

    PR NEWSWIRE

    Qilu Pharma`s Generics Icosapent Ethyl Receives Approval in US

    FDA

    Qilu Pharma`s Generics Bumetanide Receives Approval in US

    FDA

    Qilu Pharmaceutical`s Generics Sugammadex Receives Tentative Approval in US

    FDA

    Qilu`s Generics Meropenem Receives Approval in US

    FDA

    Qilu`s 3 Cancer Immunotherapy Studies At ASCO 2024

    PR NEWSWIRE

    Qilu Pharma`s Generic Cetrorelix Acetate Receives Approval in the U.S

    FDA

    Qilu Pharma Spesolimab-sbzo Receives Suppl Approval in the U.S

    FDA

    Qilu Pharma Showcases QL1706 Clinical Trial Outcomes in Oral Presentation

    PR NEWSWIRE

    Results from Trial of Qilu`s Anticancer Agent QL1706 Featured in Presentation

    PR NEWSWIRE

    Qilu`s Generic Lenalidomide Receives Approval in the U.S.

    FDA

    Results of Phase II Study on Qilu Pharmaceutical`s Novel Drug QL1706 Published

    PR NEWSWIRE

    Results of the Phase III Study on Qilu Pharmaceutical`s Iruplinalkib Published

    PR NEWSWIRE

    Qilu Pharmaceutical Announces Results from Phase I Clinical Study for QLS31905

    PR NEWSWIRE

    Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab

    PR NEWSWIRE

    Phase I Results for Qilu Pharmaceutical`s Iparomlimab (QL1604) Now Published

    PR NEWSWIRE

    Qilu Pharmaceutical announces latest results from its clinical study on QL1706

    PR NEWSWIRE

    Qilu Pharma to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

    PR NEWSWIRE

    QiLu Pharmaceutical`s Iruplinalkib Phase III Study Researched Primary Endpoint

    PR NEWSWIRE

    FDA allows more imports of key cancer med from China`s Qilu

    FIERCE PHARMA

    FDA to import more of cancer drug from China

    ENDPTS

    Qilu Announces Trials in Progress Posters on QL1706 in Phase III

    PR NEWSWIRE

    Advances of Qilu Pharmaceutical`s QL1706 in Clinical Research Presented at ASCO

    PR NEWSWIRE

    Results of PhI Study of Qilu Pharma`s PD-1/CTLA-4 Iparomlimab/Tuvonralimab

    PR NEWSWIRE

    Qilu`s Generic Gefitinib Receives Approval in the U.S.

    FDA

    Qilu Pharma Latest Results of QL1604 plus Chemotherapy as First-Line Treatment

    BIOSPACE

    CellOrigin Announces Collaboration with Qilu to Develop CAR-iMAC Cell Therapy

    PRNEWSWIRE

    CellOrigin announced collaboration with Qilu to develop CAR-iMAC cell therapy

    WFMZ

    Qilu Pharmaceutical`s Generic Imatinib Mesylate Receives Approval in US

    FDA

    Qilu Pharm Generic Pemetrexed Disodium Receives Approval in the U.S.

    FDA

    Qilu Pharmaceutical Generic Bortezomib Receives Approval in the U.S.

    FDA

    Qilu`s Generic Imatinib Mesylate Receives Approval in the U.S.

    FDA

    Qilu Pharm`s Generic Pemetrexed Receives Approval in the U.S.

    FDA

    S. Korea`s Peptron licenses global development of ADCs for cancer treatment

    BIOSPECTRUMASIA

    Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

    PRNEWSWIRE

    Qilu`s Generic Decitabine Receives Approval In US

    FDA

    Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application Vicineum™

    BUSINESSWIRE

    Cend Therapeutics and Qilu Pharmaceutical Announce Partnership

    GLOBENEWSWIRE

    Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™

    BUSINESSWIRE

    Sesen Bio and Qilu Announce IND Application for Vicineum™

    BUSINESSWIRE

    Qilu`s Generic Fosaprepitant Dimeglumine Receives Approval In US

    FDA

    Sesen Bio announces an exclusive license agreement with Qilu Pharma

    BUSINESSWIRE

    Qilu Pharm`s Generic Exemestane Receives Approval in US

    FDA

    Indian generics contenders; Chi-Med`s HK listing; Qilu Pharma explosion

    FIERCE PHARMA

    Qilu Pharm`s Generic Tadalafil Receives Approval in US

    FDA

    Qilu Pharm`s Generic Solifenacin Succinate Receives Tentative Approval in US

    FDA

    Cialis (tadalafil) : Eli Lilly vs. Qilu Pharm Co., Ltd.

    PATENT LITIGATION

    Qilu Pharm`s Generic Tadalafil Receives Approval in US

    FDA

    Qilu Pharm`s Generic Ceftriaxone Sodium Receives Approval in US

    FDA

    Qilu Pharm`s Generic Cefazolin Sodium Receives Approval in US

    FDA

    Qilu Pharma`s Generic Palonosetron Hydrochloride Receives Approval in US

    FDA

    Qilu Pharm’s Generic Premetrexed Receives Tentative Approval In US

    FDA

    Generic version of AZ’s Iressa launched in China

    PMLIVE

    Qilu Pharm Co Ltd`s Generic Oxaliplatin approved in US as chemotherapy drug

    FDA

    Camptosar ANDA Approval Adds More Competition for Generic Market

    TWOFOUR INSIGHT

    Qilu Pharm`s Generic Irinotecan HCl approved in US as an antineoplastic agent

    FDA

    China`s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts

    BLOOMBERG

    Qilu Pharm`s Generic Olanzapine approved in US as an atypical antipsychotic

    FDA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.